Want to see HK:3737 full AI Analyst Report?
3737 Stock Chart & Stats
HK$0.88
HK$0.04(4.04%)
At close: 4:00 PM EST
HK$0.88
HK$0.04(4.04%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$0.98
Previous CloseN/A
Volume157.00K
Average Volume (3M)412.77K
Market Cap
HK$592.90M
Enterprise ValueHK$527.97M
Total Cash (Recent Filing)HK$200.89M
Total Debt (Recent Filing)HK$227.02M
Price to Earnings (P/E)29.6
Beta<0.01
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.43%
Share Statistics
EPS (TTM)0.02
Shares Outstanding863,600,000
10 Day Avg. Volume391,300
30 Day Avg. Volume412,766
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.40
Price to Sales (P/S)0.25
P/FCF Ratio6.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModest leverage (debt-to-equity ~0.21) and a stable equity base provide lasting financial flexibility. This reduces refinancing risk, supports dividend and capex capacity during cycles, and gives the company breathing room to navigate industry headwinds over the next several quarters.
High Gross MarginsA roughly 54% gross margin signals durable product-level profitability and pricing power or favorable product mix. High gross margins create room to absorb SG&A or R&D, supporting margin recovery potential and resilience to cost inflation over a multi-quarter horizon.
Positive Free Cash Flow TrendReturning to positive FCF (~HK$69.9M) after earlier negative years shows the business can generate cash even amid profit pressure. Persistent cash generation supports dividend sustainability, discretionary investment and lowers reliance on external financing over coming quarters.
Bears Say
Sharp Revenue DeclineA steep revenue drop (~-21.5% YoY) undermines scale economics and indicates demand or competitive pressures. Sustained top-line weakness compresses operating leverage, limits ability to rebuild margins, and raises execution risk for returning to prior growth levels over the medium term.
Compressed Profitability And ROENet margin collapsing to ~1% and ROE falling sharply signal impaired profit conversion. Low returns reduce reinvestment capacity and shareholder capital efficiency, making it harder to fund growth or sustain dividends unless margins recover meaningfully over coming quarters.
Volatile And Falling FCFA ~48% drop in FCF highlights volatile cash conversion and rising cash strain despite positive operating cash flow. This volatility increases funding risk for capex and dividends, weakens planning visibility, and could force trade-offs in investment or payout policies over the near term.
Zhongzhi Pharmaceutical Holdings Limited News
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$0.98 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$592.90M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date is Aug 20, 2026 which is in 49 days.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.011.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Zhongzhi Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays a Annually dividend of HK$0.05 which represents an annual dividend yield of 9.43%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.176%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.77%
12-Months-Change
Fundamentals
Return on Equity
1.59%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---